Clinical Trials Logo

Filter by:
NCT ID: NCT03143452 Completed - Clinical trials for Adult Patients Undergoing Phacoemulsification With Topical Anesthesia

Comparison Between 2% Lidocaine Gel and 5% Tetracaine Eye Drop as Topical Anesthesia in Phacoemulsification

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

This study aimed to compare the efficacy between 2% lidocaine gel vs 0.5% tetracaine eye drop as topical anesthesia in phacoemulsification

NCT ID: NCT03141125 Completed - Scleroderma Clinical Trials

The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy

Start date: January 2016
Phase: N/A
Study type: Interventional

Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017

NCT ID: NCT03139591 Completed - Clinical trials for Adult Patients Undergoing Elective Surgery With General Anesthesia and LMA Insertion

Comparison Between Lidocaine Inhalation and Intravenous Dexamethasone in Reducing Pain After Laryngeal Mask Insertion

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

This study aimed to compare the efficacy between lidocaine inhalation vs intravenous dexamethasone to reduce pain after laryngeal mask insertion

NCT ID: NCT03138941 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

APLCLLDAS
Start date: September 1, 2013
Phase:
Study type: Observational [Patient Registry]

Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE). SLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe manifestations of SLE are the accrual of irreversible organ damage, especially renal and central nervous system (CNS) involvement. As there is no effective targeted monotherapy for SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and inexorably accrue permanent organ damage over time. The diversity of clinical features of active SLE has made quantification of disease activity problematic. Although there are a number of published systems in use to measure SLE disease activity, there are widely acknowledged problems with these instruments. Published definitions of remission are so stringent that they are met by less than 5% of patients. This lead to the realisation that rather than lupus remission, a lupus low disease activity state target may be more feasible, and that patients with low disease activity are more homogeneous than patients with active disease. Thus, the development of a definition of lupus low disease activity, which is feasible and has face validity, escapes the complexity of attempts to quantify heterogeneous states of active disease. In this study, the investigators will prospectively collect longitudinal data on consecutive SLE patients at each centre to evaluate the LLDAS definition. Protection from organ damage accrual as the primary endpoint.

NCT ID: NCT03134612 Completed - Clinical trials for General Anesthesia With Propofol

Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection

Start date: July 2016
Phase: Phase 2
Study type: Interventional

This study aims to compare the effectivity between ondansetron 8 mg and lidocain 40 mg in preventing pain due to propofol injection

NCT ID: NCT03134560 Completed - Clinical trials for Difficult Vein Access

Intravenous Cannulation Using Vein Display Instrument and Without Using Vein Display Instrument in Pediatric Patients

Start date: April 2016
Phase: N/A
Study type: Interventional

This study aims to compare intravenous cannulation success rate between using vein display instrument and without using vein display instrument in pediatric patients.

NCT ID: NCT03134391 Completed - Clinical trials for Adult Patient Undergoing Elective Surgery With Spinal Anesthesia

Comparison Between Vapocoolant Spray and Eutectic Mixture of Local Anesthetics in Reducing Pain From Spinal Injection

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

This study aimed to evaluate the effect of vapocoolant spray and EMLA in reducing pain from spinal injection

NCT ID: NCT03134378 Recruiting - Clinical trials for Helicobacter Pylori Infection

10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication

Start date: October 3, 2016
Phase: Phase 4
Study type: Interventional

Helicobacter pylori is a bacterium estimated to colonize in the gastrointestinal tract of the half population in the world. Colonization of this bacteria is suspected to be one of the main risk factor for the occurrence of various abnormalities of the upper gastrointestinal tract, such as peptic ulcer and gastrointestinal cancer. The Experts recommend giving triple therapy regimens as first-line eradication therapy for Helicobacter pylori infection. The recommended duration of triple therapy is 10-14 days. However, recent studies suggest triple therapy with longer duration will provide a higher percentage of eradication. This study wanted to show whether 14 days of triple therapy was better than 10 days in Helicobacter pylori eradication.

NCT ID: NCT03134287 Completed - Clinical trials for Adult Patient Undergoing Elective Surgery With General Anesthesia and Needs Nasogastric Tube Placement

Nasogastric Tube Placement on Intubated Patient: Two-Finger Method vs Reverse Sellick's Maneuver

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

The study aimed to compare the efficacy between nasogastric tube placement using Two-Finger Method and Reverse Sellick's Maneuver

NCT ID: NCT03117192 Completed - Immunosuppression Clinical Trials

Zinc Supplementation on Cellular Immunity in Thalassemia Major

Start date: September 1, 2013
Phase: Phase 4
Study type: Interventional

Randomized controlled trial was conducted in post-splenectomy patients aged >12 years. Subjects are randomly assigned to two groups (zinc and placebo). 1.5 mg/kg/day (max 50 mg/day) of Zinc is administered.